The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

Moderna (MRNA) stock hits a 52-week high to extend its YTD rally following back-to-back years of declines. Read more here.

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

Researchers from the Wilmer Eye Institute, Johns Hopkins Medicine Center for Nanomedicine—which designs nanotechnology-based ...

Regulatory uncertainty remains a common factor for both companies following an FDA memo that raised concerns about vaccine ...

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...

The only man in his immediate family to be without a cancer diagnosis, one Lynch syndrome patient made the trip to ...